Literature DB >> 33825489

Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis.

Katharina Dörr1, Michael Kammer1,2, Roman Reindl-Schwaighofer1, Matthias Lorenz3, Thomas Prikoszovich3, Rodrig Marculescu4, Dietrich Beitzke1,5, Alice Wielandner1,5, Reinhold G Erben6, Rainer Oberbauer1.   

Abstract

[Figure: see text].

Entities:  

Keywords:  fibroblast growth factor; hypertrophy; renal dialysis

Mesh:

Substances:

Year:  2021        PMID: 33825489     DOI: 10.1161/CIRCRESAHA.120.318556

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  14 in total

1.  Editorial: Narrow the gap, build a bridge: an inspirational approach to chronic kidney disease-mineral and bone disorder.

Authors:  Aline Martin; Tamara Isakova
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-07-01       Impact factor: 3.416

Review 2.  The Diabetic Cardiorenal Nexus.

Authors:  John A D'Elia; George P Bayliss; Larry A Weinrauch
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

3.  Vitamin D receptor gene polymorphism predicts left ventricular hypertrophy in maintenance hemodialysis.

Authors:  Bingman Liu; Qingqing Yang; Liangyu Zhao; Hua Shui; Xiaoyun Si
Journal:  BMC Nephrol       Date:  2022-01-15       Impact factor: 2.388

4.  Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis.

Authors:  Kevin C Maki; Meredith L Wilcox; Mary R Dicklin; Rahul Kakkar; Michael H Davidson
Journal:  BMC Nephrol       Date:  2022-01-16       Impact factor: 2.388

5.  Non-Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors:  John G Damrath; Neal X Chen; Corinne E Metzger; Shruthi Srinivasan; Kalisha O'Neill; Annabel Biruete; Keith G Avin; Joseph M Wallace; Matthew R Allen; Sharon M Moe
Journal:  JBMR Plus       Date:  2022-02-11

6.  The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis.

Authors:  Katharina Dörr; Michael Kammer; Roman Reindl-Schwaighofer; Matthias Lorenz; Rodrig Marculescu; Marko Poglitsch; Dietrich Beitzke; Rainer Oberbauer
Journal:  Front Med (Lausanne)       Date:  2022-04-26

7.  Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study.

Authors:  S Heleen Binnenmars; Georgette E Hoogslag; Stanley M H Yeung; Frank P Brouwers; Stephan J L Bakker; Wiek H van Gilst; Ron T Gansevoort; Gerjan Navis; Adriaan A Voors; Martin H de Borst
Journal:  J Am Heart Assoc       Date:  2022-07-25       Impact factor: 6.106

Review 8.  Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease.

Authors:  Katharina Dörr; Alexander Kainz; Rainer Oberbauer
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-06-10       Impact factor: 3.416

9.  A phosphate and calcium-enriched diet promotes progression of 5/6-nephrectomy-induced chronic kidney disease in C57BL/6 mice.

Authors:  J Radloff; N Latic; U Pfeiffenberger; C Schüler; S Tangermann; L Kenner; R G Erben
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

10.  FGF23 and Vitamin D Metabolism.

Authors:  Nejla Latic; Reinhold G Erben
Journal:  JBMR Plus       Date:  2021-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.